US20050043751A1
Expired / Lapsed
US
⏱️ 0.0 years remaining
Methods and devices for maintaining patency of surgically created channels in a body organ
Assignee: Broncus Medical Inc
•
Filing: 2004-07-19
•
Granted: —
•
Expires: 2024-07-19
Abstract
Abstract This is directed to methods and devices suited for maintaining an opening in a wall of a body organ for an extended period. More particularly devices and methods are directed maintaining patency of channels that alter gaseous flow within a lung to improve the expiration cycle of, for instance, an individual having chronic obstructive pulmonary disease.
Inventors
- 👤 Loc Phan
- 👤 Ed Roschak
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 00:45
CPC Classifications
A; A61; A61B; A61B17/00; A61B17/064; A61B17/08; A61B17/083; A61B17/10; A61B17/12; A61B17/12022; A61B17/12099; A61B17/12104; A61B17/00491; A61B17/00234; A61B2017/00238; A61B2017/00243; A61B2017/00247; A61B2017/00252; A61B2017/00743; A61B2017/00809; A61B18/00; A61B2018/00315; A61B2018/00541; A61F; A61F2/00; A61F2/02; A61F2/04; A61F2/06; A61F2002/068
Claims Analysis
Total Claims: 33
Claim 1
Independent Claim
119 words
1 . An implant for maintaining an opening in a wall of a body organ, the implant having a delivery state and an expanded state, the implant comprising: a support member where at least a first portion of the support member comprises a plurality of control segments folded in a curvilinear shape, upon assuming the expanded state the control segments unfold and are located circumferentially about the support member to limit expansion of the first portion of the support member, where the support member has at least a second portion unconstrained to expand beyond the first portion such that upon expansion the support member is non-cylindrical; and a composition located on the support member and comprising an antiproliferative agent.
Claim 2
Dependent Claim
119 words
1 . An implant for maintaining an opening in a wall of a body organ, the implant having a delivery state and an expanded state, the implant comprising: a support member where at least a first portion of the support member comprises a plurality of control segments folded in a curvilinear shape, upon assuming the expanded state the control segments unfold and are located circumferentially about the support member to limit expansion of the first portion of the support member, where the support member has at least a second portion unconstrained to expand beyond the first portion such that upon expansion the support member is non-cylindrical; and a composition located on the support member and comprising an antiproliferative agent.
Claim 3
Dependent Claim
53 words
2 . The implant of claim 1 , where the support member further comprises a third portion on an end of the support member opposite to that of the second portion, the third portion is unconstrained to expand beyond the first portion, such that upon expansion the support member forms a grommet shape.
Claim 4
Dependent Claim
29 words
3 . The implant of claim 1 , where the curvilinear shape is selected from a group consisting of an s-shape, a v-shape, a u-shape, and a sinusoidal shape.
Claim 5
Dependent Claim
79 words
4 . The implant of claim 1 , where the composition comprises an amount of antiproliferative agent that does not exhibit substantial cytotoxicity but controls the healing response by suppressing hyperplasia of lung tissue, to maintain patency of an artificial opening located in the airway which allows for maintaining air passage between the opening and parenchyma for a sufficient time until the healing response of the lung tissue subsides such that the opening essentially becomes a natural airway passage.
Claim 6
Dependent Claim
15 words
5 . The implant of claim 1 , where the composition further comprises a polymer.
Claim 7
Dependent Claim
37 words
6 . The implant of claim 5 , where the composition comprises both a release rate and an amount of antiproliferative substance sufficient to modify a healing response of lung tissue resulting from creation of the opening.
Claim 8
Dependent Claim
55 words
7 . The implant of claim 5 , where the polymer is selected from a group consisting of thermoplastic polymers, thermoset polymers, acrylate polymers, a blend of acrylate-methacrylate polymers, silicone elastomers, urethane elastomers, ethylene vinyl acetate polymers, polyethylene, polypropylene, PLA-PGA, PLA, PGA, polyortho-ester, polycapralactone, polyester, hydrogels, polystyrene, co-polymers of styrene-isobutylene-styrene, and combinations or blends thereof.
Claim 9
Dependent Claim
25 words
8 . The conduit of claim 5 , further comprising a dye located in the polymer to aid in identification of the implant during placement.
Claim 10
Dependent Claim
20 words
9 . The implant of claim 5 , where the composition fully covers an outer surface of the support member.
Claim 11
Dependent Claim
20 words
10 . The implant of claim 9 , where the polymer fully encapsulates an interior surface of the support member.
Claim 12
Dependent Claim
17 words
11 . The implant of claim 5 , where the support member comprises a second polymeric material.
Claim 13
Dependent Claim
17 words
12 . The implant of claim 11 , where the polymer and second polymeric material are bioabsorbable.
Claim 14
Dependent Claim
43 words
13 . The implant of claim 1 , where the support member has at least one pocket where the antiproliferative substance is located in the pocket, and further comprising a polymer at least covering the pocket to act as a barrier to release.
Claim 15
Dependent Claim
16 words
14 . The implant of claim 1 , where the support member comprises a metallic material.
Claim 16
Dependent Claim
25 words
15 . The implant of claim 1 , where the support member comprises a plurality of members forming a mesh having a plurality of interstices.
Claim 17
Dependent Claim
25 words
16 . The implant of claim 15 , where the composition further includes a polymer and the composition covers the members but not the interstices.
Claim 18
Dependent Claim
17 words
17 . The implant of claim 1 , where the antiproliferative substance comprises a microtubule stabilizing agent.
Claim 19
Dependent Claim
15 words
18 . The implant of claim 17 , where the microtubule stabilizing agent is paclitaxel.
Claim 20
Dependent Claim
17 words
19 . The implant of claim 1 , where the antiproliferative substance comprises a microtubule destabilizing agent.
Claim 21
Dependent Claim
33 words
20 . The implant of claim 19 , where the microtubule destabilizing agent is selected from the group comprising vincristine, vinblastine, podophylotoxin, estramustine, noscapine, griseofulvine, dicoumarol, a vinca alkaloid, and a combination thereof.
Claim 22
Dependent Claim
30 words
21 . The implant of claim 1 , where the antiproliferative substance comprises a substance selected from the group consisting of steroids, non-steroidal anti-inflammatories, and d-actinomycin, and a combination thereof.
Claim 23
Dependent Claim
16 words
22 . The implant of claim 1 , where the antiproliferative substance comprises a cytostatic agent.
Claim 24
Dependent Claim
28 words
23 . The implant of claim 22 , where the cytostatic agent is selected from the group consisting of: sirolimus, everolimus, ABT-578, biolimus, tacrolimus, and a combination thereof.
Claim 25
Dependent Claim
14 words
24 . The implant of claim 1 , further comprising a mucus affecting substance.
Claim 26
Dependent Claim
26 words
25 . The implant of claim 24 , where the mucus affecting substance is selected from a group consisting of mucolytics, pulmozyme, and a combination thereof.
Claim 27
Dependent Claim
23 words
26 . The implant of claim 1 , further comprising at least one visualization mark disposed on a portion of the support member.
Claim 28
Dependent Claim
25 words
27 . The implant of claim 26 , where the visualization mark comprises a stripe circumferentially disposed about at least a portion the support member.
Claim 29
Dependent Claim
20 words
28 . The implant of claim 1 , further comprising a one-way valve in fluid communication with the interior passage.
Claim 30
Dependent Claim
20 words
29 . The implant of claim 1 , further comprising an antibiotic substance carried on or within the support member.
Claim 31
Dependent Claim
17 words
30 . The implant of claim 1 , further comprising a barrier located within the support member.
Claim 32
Dependent Claim
14 words
31 . The implant of claim 1 , further comprising a fibrin reducing substance.
Claim 33
Dependent Claim
26 words
32 . The implant of claim 31 , where the fibrin reducing substance is selected from a group consisting of streptokinase, urokinase, and tissue plasminogen activator.
References Cited (Backward Citations)
US2127903A
Cited
US3874388A
Cited
US4324235A
Cited
US4534761A
Cited
US4655771B1
Cited
US4655771A
Cited
US4503569A
Cited
US4535606A
Cited
US4687482A
Cited
US4583969A
Cited
US4892099A
Cited
US4767627A
Cited
US4753236A
Cited
US5061275A
Cited
US4957508A
Cited
US4795465A
Cited
US5443843A
Cited
US4955377A
Cited
US5054483A
Cited
US5425739A
Cited
US5220924A
Cited
US5413601A
Cited
US5123917A
Cited
US5064435A
Cited
US5330500A
Cited
US5443498A
Cited
US5876445A
Cited
US5540713A
Cited
US5514154A
Cited
US5421955A
Cited
US5421955B1
Cited
US5334217A
Cited
US6019787A
Cited
US5876448A
Cited
US5366504A
Cited
US5618301A
Cited
US5607444A
Cited
US5868777A
Cited
US6309415B1
Cited
US5653746A
Cited
US5725572A
Cited
US5554181A
Cited
US5716393A
Cited
US5527324A
Cited
US5545210A
Cited
US5674298A
Cited
US5746767A
Cited
US6270515B1
Cited
US5968070A
Cited
US5741333A
Cited
US5593442A
Cited
US6176872B1
Cited
US6231587B1
Cited
US5776161A
Cited
US6334869B1
Cited
US5922019A
Cited
US6616675B1
Cited
US5810836A
Cited
US6024756A
Cited
US5713949A
Cited
US6086610A
Cited
US6689803B2
Cited
US6117911A
Cited
US6200564B1
Cited
US6702829B2
Cited
US6245057B1
Cited
US6334870B1
Cited
US5957949A
Cited
US5876434A
Cited
US20010027341A1
Cited
US6261601B1
Cited
US20010027339A1
Cited
US6451048B1
Cited
US6120534A
Cited
US6994713B2
Cited
US6391036B1
Cited
US5938697A
Cited
US6066169A
Cited
US6264690B1
Cited
US6508822B1
Cited
US6599303B1
Cited
US6920882B2
Cited
US6620176B1
Cited
US6673084B1
Cited
US6355057B1
Cited
US6511491B2
Cited
US6368658B1
Cited
US6394093B1
Cited
US6699256B1
Cited
US20020111619A1
Cited
US6692494B1
Cited
US6602263B1
Cited
US6866674B2
Cited
US6770070B1
Cited
US6635279B2
Cited
US6254632B1
Cited
US20020111620A1
Cited
US7011094B2
Cited
US20050060042A1
Cited
US7014654B2
Cited
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.